Forest Road Acquisition Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FRX research report →
About the company
Forest Road Acquisition Corp., established in 2020 and headquartered in New York, New York, is focused on identifying and executing a strategic consolidation with one or more companies. The firm aims to complete various corporate transactions, including mergers, exchanges of capital stock, asset acquisitions, stock purchases, or other forms of corporate restructuring, specifically targeting the technology, media, and telecommunications sectors.
- CEO
- Zachary Tarica
- IPO
- 2020
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on FRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.75B
- P/E
- 1.65
- PEG
- 0.00
- P/S
- 0.10
- P/B
- 0.48
- EV/EBITDA
- 0.62
- Div Yield
- 0.00%
- Gross Margin
- 71.93%
- Op Margin
- 6.98%
- Net Margin
- 5.95%
- ROE
- 33.53%
- ROIC
- 20.79%
Latest fiscal year · YoY change
- Revenue
- $251.73M-39.9%
- Gross Profit
- $183.78M-36.0%
- Op Income
- $5.53M
- Net Income
- $-2,860,000+96.0%
- EPS
- $-0.41+96.1%
- OCF Growth
- +748.9%
- FCF Growth
- +976.3%
- 52W High
- $18.20
- 52W Low
- $9.24
- 50D MA
- $10.29
- 200D MA
- $10.64
- Beta
- 0.00
- Avg Volume
- 1.57M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Beachbody beat profitability expectations in Q3, but sales declined and management said the growth turnaround is taking longer than hoped as it pivots toward a nutrition-first multichannel model.· November 10, 2026
- Q3 revenue was $45.2 million, down 24.5% year over year, but still within guidance.
- Adjusted EBITDA was $6.4 million, above the top end of guidance, marking the 12th straight positive quarter and the 5th straight quarter of double-digit margin.
- Gross margin was 70.7%; operating income was $1.3 million and net income was $3.3 million, both above the high end of guidance.
- Management said the business is shifting from fitness-first to nutrition-first, with retail, Amazon, DTC, and creator-driven marketing as the growth levers.
- The company reduced costs by more than $30 million and lowered its EBITDA breakeven to about $125 million, but Q4 revenue guidance implies continued pressure.
Total revenue was $45.2 million, down 24.5% year over year and down 8.9% sequentially. Digital revenue was $27.8 million, down 23.5% year over year, with digital subscriptions at approximately 690,000 and average digital retention of 95.4%. Nutrition and other revenue was $17.4 million, down 26.1% year over year, with nutritional subscriptions at approximately 60,000. Consolidated gross margin was 70.7%, down 93 basis points year over year. Operating income was $1.3 million and net income was $3.3 million; adjusted EBITDA was $6.4 million with a 14.1% margin. For Q4 2026, the company guided to revenue of $38 million to $42 million, net income of negative $2 million to $1 million, and adjusted EBITDA of $6 million to $9 million. It also guided to total gross margin of 68% to 70%, with digital gross margin of 86% to 88% and nutrition/other gross margin of 41% to 44%.
Carl Daikeler said the company is moving beyond its legacy MLM-driven model into a multichannel nutrition business built around Shakeology, P90X, Insanity, Shopify, Amazon, retail, and digital fitness. He emphasized that the strategy is to use the existing customer base more efficiently, improve marketing mix and retention, and build a broader portfolio of nutrition products and content that can support daily habits and longer-term engagement. His tone was candid but constructive: he acknowledged the growth reset is taking longer than expected, while stressing that the product and channel mix should create a larger opportunity over time.
Brad Ramberg focused on the financial cleanup and margin discipline. He said operating expenses fell 22.7% year over year to $30.7 million, selling and marketing expense declined to 25.6% of revenue, and the company posted $6.4 million of adjusted EBITDA, a 14.1% margin. On liquidity, cash was $27.5 million, debt was about $22.9 million, and net cash was $4.6 million; covenants are not tested as long as cash stays above $22.5 million. He also said the early-October restructuring reduced 2027 anticipated overhead by about $27 million, identified another $7 million of savings, and should bring the total spending reduction to about $34 million, while Q4 should include about $3 million of restructuring expense.
Analysts pressed management on retail sell-through, energy drink launches, digital engagement, retention, and whether the nutrition pivot is actually bringing in new customers. Management declined to disclose retailer-specific sell-through data, but said Sprouts expanded to 181 stores, Vitamin Shoppe is in 481 stores, and the Southern California energy drink test is just starting with LA Libations. On digital, Carl said retention remains around 95% and that recent engagement has been steady, but customer acquisition is more efficient on the nutrition side; management also said many recent marketing conversions were former members from the CRM base, which led them to pull back spend and rebuild the top-of-funnel approach. They also said the long-term mix target is around 50/50 digital and nutrition, possibly slightly weighted to nutrition.
The company is now profitable on an adjusted EBITDA basis and has materially lowered its cost structure, which could create operating leverage if growth reaccelerates. Management believes the new nutrition portfolio, retail distribution, Amazon, creator/affiliate marketing, and digital content can unlock a larger addressable market than the legacy model. They also pointed to strong brand recognition, good initial feedback on new products, and a path to better customer crossover between digital fitness and nutrition.
Revenue is still shrinking sharply, with Q3 down 24.5% year over year and Q4 guidance also implying further decline. Management repeatedly said growth is taking longer than expected, largely because retail planogram timing is outside its control and because new customer acquisition is not yet offsetting legacy attrition. There is also execution risk in the marketing reset, the retail rollout, and the transition to a turnkey manufacturing model, while Q4 guidance calls for lower net income and ongoing promotional pressure on nutrition margins.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 33.5%
- Shares Outstanding
- 312.16M
- Float Shares
- 104.54M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 14 | COUGHLIN CHRISTOPHER J | sell | 1,527 |
| Jul 1, 14 | COUGHLIN CHRISTOPHER J | sell | 20,000 |
| Jul 1, 14 | COUGHLIN CHRISTOPHER J | sell | 2,406 |
| Jul 1, 14 | COUGHLIN CHRISTOPHER J | sell | 7,815 |
| Jul 1, 14 | COUGHLIN CHRISTOPHER J | sell | 5,909 |
| Jul 1, 14 | Francis Perier I Jr | other | 32,636 |
| Jul 1, 14 | Francis Perier I Jr | other | 18,632 |
| Jul 1, 14 | Francis Perier I Jr | sell | 2,482 |
| Jul 1, 14 | Francis Perier I Jr | sell | 31,018 |
| Jul 1, 14 | Francis Perier I Jr | sell | 75,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FRX coverage
Recent articles, reports, and earnings notes.
No research on FRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FRX report →Fennec Pharmaceuticals (TSE:FRX) Stock Price Crosses Above 50-Day Moving Average – Here’s What Happened
defenseworld.net · Jul 28
Fennec Announces Results of Annual Meeting
globenewswire.com · Jun 10
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
globenewswire.com · May 21
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · May 18
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
seekingalpha.com · May 14
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · May 14
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
globenewswire.com · May 7
Fennec Pharmaceuticals Inc. (FENC) Q4 2025 Earnings Call Transcript
seekingalpha.com · Mar 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.